A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers

被引:63
作者
Kamada, Yoshihiro [1 ,2 ]
Ono, Masafumi [3 ]
Hyogo, Hideyuki [4 ]
Fujii, Hideki [5 ,6 ]
Sumida, Yoshio [7 ]
Mori, Kojiroh [8 ]
Tanaka, Saiyu [8 ]
Yamada, Makoto [9 ]
Akita, Maaya [1 ]
Mizutani, Kayo [1 ]
Fujii, Hironobu [1 ]
Yamamoto, Akiko [1 ]
Takamatsu, Shinji [1 ]
Yoshida, Yuichi [2 ]
Itoh, Yoshito [7 ]
Kawada, Norifumi [5 ]
Chayama, Kazuaki [4 ]
Saibara, Toshiji [3 ]
Takehara, Tetsuo [2 ]
Miyoshi, Eiji [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Osaka, Japan
[3] Kochi Med Sch, Dept Gastroenterol & Hepatol, Kochi, Japan
[4] Hiroshima Univ, Dept Gastroenterol & Metab, Hiroshima, Japan
[5] Osaka City Univ, Grad Sch Med, Dept Hepatol, Osaka 558, Japan
[6] Osaka City Juso Hosp, Dept Gastroenterol, Osaka, Japan
[7] Kyoto Prefectural Univ Med, Dept Gastroenterol & Hepatol, Kyoto, Japan
[8] Nara City Hosp, Ctr Digest & Liver Dis, Nara, Japan
[9] aMs New Otani Clin, Osaka, Japan
基金
日本学术振兴会;
关键词
FATTY LIVER-DISEASE; FUCOSYLATED HAPTOGLOBIN; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; NATURAL-HISTORY; SEVERELY OBESE; SCORING SYSTEM; CELL-LINES; N-GLYCANS; FIBROSIS;
D O I
10.1002/hep.28002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is a growing medical problem; thus, discriminating nonalcoholic steatohepatitis (NASH) from NAFLD is of great clinical significance. For the diagnosis of NASH, liver biopsy-proven histological examination is the current gold standard, and noninvasive and reliable biomarkers are greatly needed. Recently, we found that two glycobiomarkers, fucosylated haptoglobin (Fuc-Hpt) and Mac-2 binding protein (Mac2bp), are useful independently for NASH diagnosis. In this study, we confirmed that serum Fuc-Hpt is suitable for the prediction of ballooning hepatocytes and that serum Mac2bp is suitable for the prediction of liver fibrosis severity in 124 biopsy-proven NAFLD patients (training cohort). In addition, we found that the combination of serum Fuc-Hpt and Mac2bp levels was an excellent tool for NASH diagnosis. Using receiver operating characteristic analyses, the area under the receiver operating characteristic curve, sensitivity, and specificity of the combination of these two glycobiomarkers were 0.854, 81.1%, and 79.3%, respectively. We established a prediction model for NASH diagnosis using logistic regression analysis: logit (p)=-2.700+0.00242 x Fuc-Hpt+1.225 x Mac2bp. To validate the prediction model, another 382 biopsy-proven NAFLD patients were enrolled (validation cohort). In the validation cohort, the area under the receiver operating characteristic curve of this model for NASH diagnosis was 0.844, with 71.4% and 82.3% sensitivity and specificity, respectively. In addition, we investigated the significance of our developed NASH diagnosis model in ultrasound-diagnosed NAFLD subjects who received medical health checkups (n=803). Our model also could predict NAFLD disease severity in this larger population. Conclusion: The combination of serum Fuc-Hpt and Mac2bp can distinguish NASH from NAFLD patients. Our noninvasive model using two serum glycobiomarkers contributes to a novel NASH diagnostic methodology that could replace liver biopsy. (Hepatology 2015;62:1433-1443)
引用
收藏
页码:1433 / 1443
页数:11
相关论文
共 41 条
[1]   Regression models for ordinal responses: A review of methods and applications [J].
Ananth, CV ;
Kleinbaum, DG .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1997, 26 (06) :1323-1333
[2]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[3]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[4]   Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients [J].
Artini, M ;
Natoli, C ;
Tinari, N ;
Costanzo, A ;
Marinelli, R ;
Balsano, C ;
Porcari, P ;
Angelucci, D ;
DEgidio, M ;
Levrero, M ;
Iacobelli, S .
JOURNAL OF HEPATOLOGY, 1996, 25 (02) :212-217
[5]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[6]   Histopathology of nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Tiniakos, Dina G. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (42) :5286-5296
[7]   Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma [J].
Bugianesi, E ;
Leone, N ;
Vanni, E ;
Marchesini, G ;
Brunello, F ;
Carucci, P ;
Musso, A ;
De Paolis, P ;
Capussotti, L ;
Salizzoni, M ;
Rizzetto, M .
GASTROENTEROLOGY, 2002, 123 (01) :134-140
[8]   Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics [J].
Callewaert, N ;
Van Vlierberghe, H ;
Van Hecke, A ;
Laroy, W ;
Delanghe, J ;
Contreras, R .
NATURE MEDICINE, 2004, 10 (04) :429-434
[9]   The HCV serum proteome: a search for fibrosis protein markers [J].
Cheung, K. J. ;
Tilleman, K. ;
Deforce, D. ;
Colle, I. ;
Van Vlierberghe, H. .
JOURNAL OF VIRAL HEPATITIS, 2009, 16 (06) :418-429
[10]   Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese [J].
Dixon, JB ;
Bhathal, PS ;
O'Brien, PE .
GASTROENTEROLOGY, 2001, 121 (01) :91-100